Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane (NCT01319721) | Clinical Trial Compass
CompletedNot Applicable
Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane
China96 participantsStarted 2010-12
Plain-language summary
To compare the outcomes of limbal conjunctival autograft (LCAG) versus amniotic membrane graft (AMG) when combined with intraoperative 0.02% mitomycin C (MMC) after pterygium removal in patients with recurrent pterygium.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The patients had one or two eye(s) with unilateral recurrent pterygium.
* Recurrent pterygium：be defined as of fibrovascular tissue onto the cornea for any distance in the position of a previous pterygium.
* Willingness to participate in research project and to attend research time.
Exclusion Criteria:
* Poor general health.
* Pregnant or lactating women.
* Patients with collagen vascular diseases or other autoimmune diseases.
* Patients with any evidence of stem cell deficiency.
* Patients with glaucoma who might require future filtering surgery.
* Patients with ocular infection.
* Patients with an allergy to mitomycin C, tobramycin or dexamethasone.